O
Orca Bio
Precision cell therapies for blood cancer transplants
About Orca Bio
Orca Bio is a commercial-stage biotechnology company based in Menlo Park, California, that develops high-precision allogeneic cell therapies for blood cancers and other serious diseases of the blood and immune system. The company was founded in 2016 by scientists and operators from Stanford University's stem cell research community, and its work centres on improving allogeneic hematopoietic stem cell transplantation, a potentially curative but often toxic procedure used to treat leukemias and related disorders.
At the core of the company is a proprietary manufacturing platform that sorts donor blood with single-cell precision. Instead of infusing a largely unprocessed graft, Orca Bio isolates and combines defined populations of regulatory T cells, hematopoietic stem and progenitor cells and conventional T cells, producing a personalised product for each patient. The aim is to replace a patient's diseased blood and immune system with a healthy one while lowering the risk of graft-versus-host disease and reducing the need for broad immunosuppression.
The company's lead product, TREGZI, known in clinical development as Orca-T, received U.S. FDA approval in June 2026 for use in matched-donor stem cell transplantation in adults with hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes. Its second-generation candidate, Orca-Q, is being studied in haploidentical and mismatched donor settings, and both therapies are being evaluated with reduced-intensity and nonmyeloablative conditioning to reach older or less fit patients.
Orca Bio serves transplant centres, hematologists and oncologists, and runs its own cell processing and manufacturing operations in Sacramento, California, with additional East Coast capacity planned to support commercial scale. Its pipeline also targets autoimmune diseases that could benefit from immune system reset.
Source: Dealroom company dataNews
Open roles
Orca Bio in the North Fair Oaks ecosystem
The Orca Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A1 investor entered at this stage
Series B and later6 investors entered at this stage
+ND Capital
Kaiser Permanente
IMRF
8VC
Mubadala Capital
Silicon Valley Bank
Source: Dealroom Talent Intelligence.
Patents
8 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Orca Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



